(Press-News.org) CAMBRIDGE, Mass., August 15, 2013 – Aileron Therapeutics, Inc., a clinical stage biopharmaceutical company that is developing first-in-class therapeutics based on its proprietary Stapled Peptide drug platform, announced today the publication of preclinical data on ATSP-7041, a potent and selective stapled peptide re-activator of the wild type p53 tumor suppressor protein. P53, known as "the guardian of the genome" because it repairs damaged DNA or triggers cell death in pre-cancerous cells, is one of the most important known tumor suppressors, as it is shown to be inactivated in virtually all human cancers. As 50% of all cancers circumvent P53's protective mechanisms by the over-expression of the inhibitory proteins MDM2 and MDMX, Aileron's stapled peptide is novel in that it can selectively bind to and inhibit both proteins equally and, thereby, restore the P53 function. The research, published in Proceedings of the National Academy of Sciences (PNAS), provides the first detailed publication by Aileron of one of its cell penetrating peptides that is a precursor molecule to one that the company is developing for the treatment of both liquid and solid tumors. The paper, entitled "Stapled α−Helical Peptide Drug Development: A Potent Dual Inhibitor of MDM2 and MDMX for p53-Dependent Cancer Therapy," expands on data reported by the company in poster presentations at the 2012 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics and the 2013 International MDM2 workshop in Cambridge, England.
"As evidenced by the multitude of research and clinical efforts, the full activation of p53 has been the goal of cancer researchers for decades given its [ubiquitous] role in all human cancers" said Joseph A. Yanchik III, president and chief executive officer of Aileron Therapeutics. "Our stapled peptide drug will be the first full-activator of wild type p53 of its kind to our knowledge to enter clinical trials. Our unique approach to restore p53 activity through direct inhibition of both MDM2 and MDMX has the potential to deliver greater efficacy and safety than existing small molecule approaches, which are primarily limited to inhibition of just MDM2. We look forward to advancing the p53 program into clinical trials next year that will represent our second stapled peptide drug to enter human clinical trials."
Key findings from the paper showed that ATSP 7041:
suppressed tumor growth in animal models of multiple human xenograft models, including breast cancer and bone cancer
is an equipotent dual inhibitor of MDM2 and MDMX that restores p53 specific activity
is a peptide that efficiently penetrated cell membranes and exhibited a more durable on mechanism effect on p53 signaling than small-molecule MDM2-selective inhibitors
exhibited favorable drug-like and pharmacokinetic properties that can support convenient clinical dosing regimens [including the potential for once-weekly dosing]
###
About ATSP-7041
ATSP-7041 is a precursor molecule to a more potent and selective molecule that is currently undergoing IND enabling studies and is planned for entry into Phase 1 clinical testing in 2014. It is anticipated that the clinical molecule will be studied in both liquid and solid tumor patients who test for wild-type p53. Examples of p53 dependent cancers include, AML, CML, breast cancer, liposarcoma, melanoma, and colon cancer.
About Stapled Peptides
Stapled Peptides is an emerging class of drugs with a unique set of properties that fully capitalize on 25 years of genetic research to attack drivers of complex diseases, including cancer, endocrine/metabolic disorders and inflammation. Aileron's proprietary Stapled Peptide drug platform locks peptides into their biologically active shape and imparts unprecedented pharmaceutical stability within the body. Stapled Peptide drugs are derived from natural peptides and are designed to potently and specifically target protein-protein interactions both inside and outside the cell. This new class of drugs represents a fundamentally new therapeutic approach to modulate signaling pathways to treat human disease.
About Aileron Therapeutics
Aileron Therapeutics is a clinical stage biopharmaceutical company that is developing first-in-class therapeutics based on its proprietary Stapled Peptide drug platform. With its proprietary Stapled Peptide platform, Aileron aims to dramatically improve the treatment of a wide range of diseases – including cancer and metabolic and endocrine conditions – and positively impact the lives of millions of patients. Aileron's lead drug development programs are its p53 re-activator for the treatment of cancer, and ALRN-5281, a long-acting, growth hormone releasing hormone (GHRH) for adult growth hormone deficiency that is currently in Phase 1 clinical trials. For more information, please visit http://www.aileronrx.com.
Data: ATSP-7041 as first-in-class p53 pathway re-activator for solid/ hematologic cancers
Preclinical results published in PNAS show potent, cell penetrating stapled peptide fully activates p53 and suppresses tumor growth in animal models
2013-08-15
ELSE PRESS RELEASES FROM THIS DATE:
New chemotherapy hope for hard-to-treat childhood cancers
2013-08-15
Children with a particularly lethal cancer could benefit from potentially life-saving treatment, following breakthrough work led by researchers at the University of New South Wales (UNSW).
A whole new class of drugs has been developed that, for the first time, targets the structure of the cancer cell.
UNSW researchers have provided proof that the therapy is effective in two types of cancers in the animal model. They are neuroblastoma, a cancer that affects children, and melanoma. The resulting paper has been published in Cancer Research.
"It is much like what happens ...
Evidence for a therapeutic effect of Braintone on ischemic brain damage
2013-08-15
Recently, the importance of the neurovascular unit, which is comprised of neurons, endothelial cells and astrocytes, has received great attention in the field of stroke, because stroke affects not only neurons, but also astrocytes and microvessels. Within the neurovascular unit, endothelial cells are critical for maintaining normal hemodynamic and metabolic homeostasis. Vascular damage during ischemia often leads to the disruption of the blood-brain barrier and dysregulation of vascular tonus, eventually causing substantial cell death. The Chinese herbs Rhodiolase, Notoginseng, ...
Cell cycle-related genes in the pathogenesis of neural tube defects
2013-08-15
In the field of developmental neurobiology, accurate and ordered regulation of the cell cycle and apoptosis are crucial factors contributing to the normal formation of the neural tube. Preliminary studies by Xinjun Li and colleagues from Deyang People's Hospital have identified several genes involved in the development of neural tube defects. Their recent study published in the Neural Regeneration Research (Vol. 8, No. 20, 2013) established a model of developmental neural tube defects by administration of retinoic acid to pregnant rats. Gene chip hybridization analysis ...
What is the new target inhibiting the progression of Alzheimer's disease?
2013-08-15
To stop the progression of Alzheimer's disease in the early stage, it is necessary to identify new therapeutic targets. Prof. Yunpeng Cao and team from the First Affiliated Hospital of China Medical University examined striatal-enriched phosphatase 61 expression in the brain tissues of Alzheimer's disease rats using in vivo and in vitro models, and analyzed the molecular mechanism by which striatal-enriched phosphatase 61 regulates N-methyl-D- aspartate receptor 2B transport. The researchers found that valeric acid (AP5), an N-methyl-D-aspartate receptor antagonist, significantly ...
Dragonflies can see by switching 'on' and 'off'
2013-08-15
Researchers at the University of Adelaide have discovered a novel and complex visual circuit in a dragonfly's brain that could one day help to improve vision systems for robots.
Dr Steven Wiederman and Associate Professor David O'Carroll from the University's Centre for Neuroscience Research have been studying the underlying processes of insect vision and applying that knowledge in robotics and artificial vision systems.
Their latest discovery, published this month in The Journal of Neuroscience, is that the brains of dragonflies combine opposite pathways - both an ...
Malware bites and how to stop it
2013-08-15
Antivirus software running on your computer has one big weak point - if a new virus is released before the antivirus provider knows about it or before the next scheduled antivirus software update, your system can be infected. Such zero-day infections are common.
However, a key recent development in antivirus software is to incorporate built-in defences against viruses and other computer malware for which they have no prior knowledge. These defences usually respond to unusual activity that resembles the way viruses behave once they have infected a system. This so-called ...
Graphene nanoscrolls are formed by decoration of magnetic nanoparticles
2013-08-15
Researchers at Umeå University, together with researchers at Uppsala University and Stockholm University, show in a new study how nitrogen doped graphene can be rolled into perfect Archimedean nano scrolls by adhering magnetic iron oxide nanoparticles on the surface of the graphene sheets. The new material may have very good properties for application as electrodes in for example Li-ion batteries.
Graphene is one of the most interesting materials for future applications in everything from high performance electronics, optical components to flexible and strong materials. ...
Making the brain take notice of faces in autism
2013-08-15
Philadelphia, PA, August 15, 2013 – Difficulty in registering and responding to the facial expressions of other people is a hallmark of autism spectrum disorder (ASD). Relatedly, functional imaging studies have shown that individuals with ASD display altered brain activations when processing facial images.
The hormone oxytocin plays a vital role in the social interactions of both animals and humans. In fact, multiple studies conducted with healthy volunteers have provided evidence for beneficial effects of oxytocin in terms of increased trust, improved emotion recognition, ...
Heartbeats link mind and body together
2013-08-15
While we're not necessarily aware of our heartbeat, this inner rhythm actually contributes to how we experience the body, and what belongs to it, according to research recently conducted at EPFL. A study to be published in the journal Psychological Science later this year supports the idea that signals from our internal organs combine with visual information to contribute to self-consciousness.
"The relevance of internal organs for identifying the self was determined over a decade ago," says EPFL researcher Olaf Blanke. "What is new about our approach and findings is that ...
Characteristics of family killers revealed by first taxonomy study
2013-08-15
Of all the dark forms that murder can take, the slaying of a family by the father is one of the most tragic and the least understood. This first ever study of British 'family annihilators', published in the Howard Journal of Criminal Justice, has analysed three decades of cases and reveals four new types of annihilator.
"Family annihilators have received little attention as a separate category of killer," said Professor David Wilson, one of the paper's three authors, and Director of the Centre of Applied Criminology at Birmingham City University. "Often they are treated ...
LAST 30 PRESS RELEASES:
Survey of 12 European countries reveals the best and worst for smoke-free homes
First new treatment for asthma attacks in 50 years
Certain HRT tablets linked to increased heart disease and blood clot risk
Talking therapy and rehabilitation probably improve long covid symptoms, but effects modest
Ban medical research with links to the fossil fuel industry, say experts
Different menopausal hormone treatments pose different risks
Novel CAR T cell therapy obe-cel demonstrates high response rates in adult patients with advanced B-cell ALL
Clinical trial at Emory University reveals twice-yearly injection to be 96% effective in HIV prevention
Discovering the traits of extinct birds
Are health care disparities tied to worse outcomes for kids with MS?
For those with CTE, family history of mental illness tied to aggression in middle age
The sound of traffic increases stress and anxiety
Global food yields have grown steadily during last six decades
Children who grow up with pets or on farms may develop allergies at lower rates because their gut microbiome develops with more anaerobic commensals, per fecal analysis in small cohort study
North American Early Paleoindians almost 13,000 years ago used the bones of canids, felids, and hares to create needles in modern-day Wyoming, potentially to make the tailored fur garments which enabl
Higher levels of democracy and lower levels of corruption are associated with more doctors, independent of healthcare spending, per cross-sectional study of 134 countries
In major materials breakthrough, UVA team solves a nearly 200-year-old challenge in polymers
Wyoming research shows early North Americans made needles from fur-bearers
Preclinical tests show mRNA-based treatments effective for blinding condition
Velcro DNA helps build nanorobotic Meccano
Oceans emit sulfur and cool the climate more than previously thought
Nanorobot hand made of DNA grabs viruses for diagnostics and blocks cell entry
Rare, mysterious brain malformations in children linked to protein misfolding, study finds
Newly designed nanomaterial shows promise as antimicrobial agent
Scientists glue two proteins together, driving cancer cells to self-destruct
Intervention improves the healthcare response to domestic violence in low- and middle-income countries
State-wide center for quantum science: Karlsruhe Institute of Technology joins IQST as a new partner
Cellular traffic congestion in chronic diseases suggests new therapeutic targets
Cervical cancer mortality among US women younger than age 25
Fossil dung reveals clues to dinosaur success story
[Press-News.org] Data: ATSP-7041 as first-in-class p53 pathway re-activator for solid/ hematologic cancersPreclinical results published in PNAS show potent, cell penetrating stapled peptide fully activates p53 and suppresses tumor growth in animal models